JP2025011142A5 - - Google Patents
Info
- Publication number
- JP2025011142A5 JP2025011142A5 JP2024168470A JP2024168470A JP2025011142A5 JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5 JP 2024168470 A JP2024168470 A JP 2024168470A JP 2024168470 A JP2024168470 A JP 2024168470A JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5
- Authority
- JP
- Japan
- Prior art keywords
- application
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773885P | 2018-11-30 | 2018-11-30 | |
| US62/773,885 | 2018-11-30 | ||
| US201962826462P | 2019-03-29 | 2019-03-29 | |
| US62/826,462 | 2019-03-29 | ||
| PCT/US2019/064032 WO2020113224A2 (en) | 2018-11-30 | 2019-12-02 | Chimeric antigen receptor factories and methods of use thereof |
| JP2021530875A JP7649239B2 (ja) | 2018-11-30 | 2019-12-02 | キメラ抗原受容体ファクトリおよびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530875A Division JP7649239B2 (ja) | 2018-11-30 | 2019-12-02 | キメラ抗原受容体ファクトリおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025011142A JP2025011142A (ja) | 2025-01-23 |
| JP2025011142A5 true JP2025011142A5 (cg-RX-API-DMAC7.html) | 2025-10-15 |
| JP7886110B2 JP7886110B2 (ja) | 2026-07-07 |
Family
ID=70853578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530875A Active JP7649239B2 (ja) | 2018-11-30 | 2019-12-02 | キメラ抗原受容体ファクトリおよびその使用方法 |
| JP2024168470A Active JP7886110B2 (ja) | 2018-11-30 | 2024-09-27 | キメラ抗原受容体ファクトリおよびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530875A Active JP7649239B2 (ja) | 2018-11-30 | 2019-12-02 | キメラ抗原受容体ファクトリおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12577311B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3887509A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7649239B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210135475A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3119644A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020113224A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
| JP7680967B2 (ja) * | 2019-06-14 | 2025-05-21 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Pd-1に対する抗体およびその使用方法 |
| AU2020291946B2 (en) * | 2019-06-14 | 2026-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| EP4226972A4 (en) * | 2020-10-12 | 2025-01-01 | Nanjing Iaso Biotechnology Co., Ltd. | CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4355358A1 (en) * | 2021-06-15 | 2024-04-24 | Allogene Therapeutics, Inc. | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
| CN114565761B (zh) * | 2022-02-25 | 2023-01-17 | 无锡市第二人民医院 | 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法 |
| EP4536296A1 (en) * | 2022-06-09 | 2025-04-16 | Telix Pharmaceuticals (Innovations) Pty Ltd | Combination therapy |
| TW202442689A (zh) * | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| WO2026117664A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Engineered cells and uses thereof for treating cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| BR112013021562B1 (pt) * | 2011-03-16 | 2023-01-10 | Argenx Bvba | Anticorpos para cd70 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| CA2962949C (en) | 2014-10-06 | 2024-03-05 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| US20180334490A1 (en) * | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| WO2016100980A1 (en) | 2014-12-19 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof |
| RU2017125531A (ru) | 2014-12-19 | 2019-01-21 | Дана-Фарбер Кэнсер Инститьют, Инк. | Химерные антигенные рецепторы и способы их применения |
| WO2016149578A1 (en) | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| US20190031759A1 (en) * | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| EP3288977B1 (en) | 2015-05-01 | 2021-11-17 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
| WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| EP3583129B1 (en) * | 2017-02-14 | 2021-11-03 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
| EP3585817A4 (en) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2019178356A1 (en) | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Engineered cells, t cell immune modulating antibodies and methods for using the same |
-
2019
- 2019-12-02 JP JP2021530875A patent/JP7649239B2/ja active Active
- 2019-12-02 WO PCT/US2019/064032 patent/WO2020113224A2/en not_active Ceased
- 2019-12-02 KR KR1020217019851A patent/KR20210135475A/ko active Pending
- 2019-12-02 CA CA3119644A patent/CA3119644A1/en active Pending
- 2019-12-02 EP EP19889550.0A patent/EP3887509A4/en active Pending
- 2019-12-02 US US17/298,271 patent/US12577311B2/en active Active
-
2024
- 2024-09-27 JP JP2024168470A patent/JP7886110B2/ja active Active